

**AFRICAN JOURNAL OF
MEDICINE**
and medical sciences

VOLUME 29, NUMBER 2, JUNE 2000



**EDITOR:
B. O. OSOTIMEHIN**

**ASSISTANT EDITOR:
A. O. UWAIFO**

ISSN 1116 — 4077

Immune response to aflatoxin B₁-histone H₁ Complex

OA Odunola and AO Uwaifo

Cancer Research Laboratories, Department of Biochemistry, College of Medicine,
University of Ibadan, Ibadan, Nigeria.

Summary

Antibodies against aflatoxin B₁ have been raised in rabbits using aflatoxin B₁-histone H₁ conjugates as immunogen. Aflatoxin B₁ was coupled to histone H₁ via the ultimate carcinogen aflatoxin B₁-2, 3-epoxide. The antibodies are specific for aflatoxin B₁. The average number of binding sites on the antibody molecules for aflatoxin B₁ as obtained from Scatchard plot analysis of the binding data is 1.94 with $\Delta F^\circ = -6.19$ Kcal/mol, while the average association constant for the binding is 34.5×10^3 M⁻¹. Male wistar rats after immunization with aflatoxin B₁-histone H₁ showed lower mortality and reduction of acute toxic effects in the liver when challenged with a single dose of aflatoxin B₁. The antibodies may be useful in immunoprophylaxis against aflatoxicosis.

Keywords: Aflatoxin B₁-histone H₁-complex, immunoprophylaxis.

Résumé

On a élevé des anti-corps dans les lapins contre l'aflatoxine B₁ en utilisant comme immunogène la combinaison aflatoxine B₁-histone H₁. On a accouplé l'aflatoxine B₁ et l'histone H₁ à travers l'ultime carcinogène aflatoxine B₁-2, 3-époxyde. Les anti-corps sont spécifiquement destinés à l'aflatoxine B₁. Le nombre moyen de sites contraignants sur les molécules d'anti-corps pour l'aflatoxine B₁, obtenu de l'analyse du terrain de scatchard sur les données de combinaison, est de 1,94 avec $\Delta F^\circ = -6,19$ Kcal/mol, tandis que la constante d'association moyenne pour l'élément de combinaison est de $34,5 \times 10^3$ M⁻¹. Les rats wistars mâles, après avoir été vaccinés avec la combinaison de l'aflatoxine B₁-histone H₁, faisaient preuve de mortalité moins fréquente et de toxicité moins aiguë dans leurs foies sous l'impact d'une seule dose de l'aflatoxine B₁. Les anti-corps pourraient servir d'immunoprophylaxie contre l'aflatoxicose.

Introduction

The cytotoxicity, mutagenicity and carcinogenicity of aflatoxin B₁ (AFB₁) in various cells have been well-documented [1-3]. This mycotoxin has been shown to interact both *in vivo* and *in vitro* after metabolic activation with serum albumin [4] and target cell nuclear DNA especially within the rRNA gene sequences [5]. In addition to DNA and RNA's [6], AFB₁ also interact with nuclear proteins especially the lysine rich: histone H₁ protein [7]. Antibodies raised against DNA and serum albumin adducts of aflatoxins are being used in the immunodetection and immunodiagnosis of these toxins [8-10]. It was therefore thought desirable to assess the immunological potentials of aflatoxin B₁-histone H₁ (AFB₁-H₁) complex.

Correspondence: Dr. O.A. Odunola, Cancer Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria.

Furthermore, the use of macromolecular carriers such as DNA, serum albumin and histone H₁ which are *in vivo* targets of AFB₁ in raising antibodies against the toxin may give an insight into possible immune response to such complexes that may be formed during the toxins' biochemical interactions with the carriers *in vivo*. Such knowledge is likely to reveal their potential use in immunoprophylaxis against aflatoxins.

We report here the coupling of AFB₁ to histone H₁, characterisation of antibodies to the complex and the protective effect of the antibodies on AFB₁-induced hepatic toxicities.

Materials and methods

Aflatoxin B₁, histone H₁, nicotinamide adenine diphosphate (NADP), glucose-6-phosphate (G6P) and dimethylsulphoxide (DMSO) were purchased from Sigma Chemical Co. (St. Louis, Mo.). Aroclor 1254 was from Monsanto, Co. (St. Louis, Mo.). Sephadex G-100 was purchased from Pharmacia Fine Chemical, Inc., while cellulose acetate strips were from Gelman Instrument Co. Complete Freund's adjuvant and *Mycobacterium tuberculosis* (H37Ra) were obtained from Difco Laboratories (Detroit, M.I.). Male albino rabbits of approximately 2 kg size and male albino wistar rats approximately 200 g size were obtained from the Central Animal House, College of Medicine, University of Ibadan, Ibadan, Nigeria. All chemicals and organic solvents were either reagent grade or chemically pure.

Preparation of rat liver homogenate fraction (S₉)

The rat liver microsomal fraction (S₉) (a postmitochondrial supernatant at 9,000 g) was prepared according to the method of Maron and Ames, 1983 [11]. Male albino wistar rats weighing approximately 200 g each were used. The rat liver enzymes were first induced with Aroclor 1254 (a polychlorinated biphenyl (PCB) mixture). Aroclor 1254 was diluted in corn oil to a concentration of 200 mg/ml and a single intraperitoneal (i.p.) injection of 500 mg/kg was administered to each of the rat five days before sacrifice. The rats were given rat cubes (from Ladokun Livestock Feeds, Ibadan, Nigeria) and drinking water *ad libitum* until 12 hours before sacrifice when the food alone was removed.

All the steps involved in the preparation of the S₉ fraction were carried out at 0-4 °C using cold, sterile solutions and glasswares. On the fifth day of induction, the rats were killed by cervical dislocation and their livers excised aseptically using sterile surgical tools. The freshly excised livers were placed in preweighed beakers containing approximately 1 ml of chilled 0.15M KCl/g of wet liver. After weighing, the livers were washed several times in fresh, chilled KCl, transferred to

a beaker containing 3 volumes of 0.15M KCl (3 ml/g wet liver) and homogenized. The homogenate was centrifuged at 9,000 g for 15 minutes at 4 °C in the MSE 18 refrigerated centrifuge. The supernatant (the S₉ fraction) was decanted, sterilized by filtration through a 0.22 μm filter under positive pressure, distributed in 2 ml portions in small plastic Nunc tubes and stored immediately at -80 °C.

The sterility of the preparation was determined by plating 0.1 ml of the S₉ homogenates on minimal agar containing histidine and biotin.

Preparation of immunogen

The immunogen aflatoxin B₁-histone H₁ (AFB₁-H₁), was prepared by a modification of the methods of Gurtoo, [12] and Essigmann *et al.* [3]. The incubation mixture for the conjugation of AFB₁ to histone H₁ included sodium phosphate buffer (NAPB) (pH 7.4; 100 mM); MgCl₂ (8 mM); KCl (33 mM); G6P (5 mM); NADP (4 mM); approximately 1mg of S₉ microsomal proteins (prepared as described above) per ml of 1% w/v histone H₁ in NAPB and AFB₁ in DMSO. The molar ratio of hapten to carrier protein in the reaction mixture was 25. The reaction mixture was agitated at 37 °C for 90-minutes in complete darkness. The mixture was subsequently dialyzed against seven changes of distilled water in the dark at 0 °C to 4 °C for 24 hours to remove the free hapten AFB₁.

The crude suspension of AFB₁-H₁ complex was further purified on sephadex G-100 column. Eluate from the column was concentrated by vacuum dialysis at 0 °C-4 °C. The concentrated suspension of AFB₁-H₁ was distributed into evaporation dishes and allowed to dry under vacuum in a desiccator at 0 °C - 4 °C.

The above procedure was repeated except that the S₉ microsomal proteins were denatured at 100 °C for 10 mins before being added to the reaction mixture followed by AFB₁.

The dried crystals from each of the reaction medium were separately pooled and stored desiccated in amber coloured bottles at 4 °C. Samples from the two stock crystals were analysed for covalent binding between AFB₁ and H₁ and for immunochemical properties.

Solvent extraction

One percent aqueous solution of samples of AFB₁-H₁ complex from the first and second mixtures were separately extracted with 10 ml chloroform for 10mins and were allowed to stand in the dark for 30mins during which the aqueous and chloroform layers separated. The two layers were subsequently examined under the long wavelength ultraviolet light for the presence of the blue fluorescence characteristic of AFB₁.

Electrophoresis

Samples from three (0.75%, 3%, 15%) aqueous solutions of AFB₁-H₁ complex from the first reaction medium were run on two cellulose acetate strips at 0.4mA per centimeter of strip width for two hours in Barbitol buffer (pH 8.6 0.1). After electrophoresis one of the strips was stained with Ponceau S while the unstained strip was observed under the long wavelength ultraviolet light for fluorescence (Figure 1).




Fig.1: Cellulose acetate electropherogram of aflatoxin B₁-histone H₁ complex. Three dilution of AFB₁-H₁ aqueous solution (0.75%; 3%; 15%) were run on the two cellulose acetate strips at 0.4mA per centimeter of strip width in Barbitol buffer (pH 8.6 0.1) for 2 hours. S:- stained with Ponceau S, F:- unstained and photographed under long wavelength ultra violet light.

Spectrophotometric analysis

The UV spectra of AFB₁-H₁ complex from the first reaction medium, pure AFB₁ and pure histone H₁ were obtained in saline for comparison (Figure 2).

The amount of AFB₁ bound to histone H₁ in the complex obtained from the first reaction mixture was determined spectrophotometrically after the conjugate had been extracted with chloroform [14]. Data obtained from both the unreacted toxin or the toxin conjugated to protein were used for final calculation.

Production of antibodies against AFB₁-H₁

Antibodies to AFB₁-H₁ complex were raised in three rabbits after they had been separately injected intradermally with 2 ml of water in oil emulsion of the complex (66.67 μg protein/ml) at 20 to 40 sites along the shaved area of their back [15]. The water in oil emulsion was prepared by dissolving 1 mg AFB₁-H₁ in 5 ml 0.9% NaCl. 10ml complete Freund's adjuvant and additional 10mg *Mycobacterium tuberculosis* were added to the solution to give a water in oil emulsion with final concentration of 66.67 ug protein




Fig. 2: UV spectra of aflatoxin B₁ (AFB₁); aflatoxin B₁-histone H₁ complex (AFB₁-H₁) and histone H₁ (H₁) in saline.

per ml of emulsion. 2 ml of saline was injected into three control rabbits. Trial bleedings were made through the inner marginal vein of each of the rabbit's right ear once every week starting from the third week to the twelfth week after immunization. For each week, the presence of serum antibodies to AFB₁-H₁ was detected by the interfacial ring test where a solution of the antiserum was carefully overlaid with that of the complex. Precipitate formation was then examined around the interface. The antibody titers of the immunized rabbits were also determined on a weekly basis (Fig. 3).




Fig. 3: Antibody titres of the rabbits after immunization with aflatoxin B₁-histone H₁ complex. Each point on the graph is the mean of the data obtained for the three rabbits in the ten weeks under study.

Immunoglobulin G (IgG) was prepared and purified from the weekly antisera and control sera as follows: - IgG was separated from the serum samples by three precipitations with saturated ammonium sulphate solution at a final concentration of 33.3%. The third precipitate was dissolved and dialysed against borate buffered saline and finally against sodium phosphate buffer (NaPB) at pH 6.3. It was further purified by chromatography on a diethylaminoethyl cellulose column, which had been equilibrated with NaPB at pH 6.3. IgG was eluted from the column with the same buffer, pooled, concentrated and stored frozen for subsequent tests. Immunoglobulin concentration in the weekly samples was determined spectrophotometrically at 278 nm using an absorptivity ($E^{1\%}$) of 15.5. The specificity of the IgG antibodies for AFB₁ was determined using the hapten inhibition reaction [16]. Figure 4 shows the inhibition curve for the reaction.

Physicochemical characterisation of the antibodies against AFB₁-H₁ complex.

Equilibrium dialysis method was utilized to study the binding properties of the antibodies from the immunized rabbits with AFB₁. AFB₁ solution was prepared in borate buffered saline in a concentration range of 50, 20, 10, 5 and 1 µM respectively. The dialysis tubing holding 0.5 ml antibody globulin from each antiserum sample was placed in the appropriate AFB₁ solution. The solutions were refrigerated in the dark for 24 hours to allow for equilibration. Controls consisting of 0.5 ml

globulin from control rabbits were similarly treated. The amount of free aflatoxin in equilibrium with bound aflatoxin was estimated spectrophotometrically at 363 nm. The amount of IgG bound AFB₁ was determined as earlier described [17]. The binding constant and the number of binding sites were analysed using the Scatchard equation [18] assuming the law of mass action. (Fig. 5).




Fig. 4: Inhibition of binding of rabbit immunoglobulin G antibodies to aflatoxin B₁-histone H₁ complex in the presence of aflatoxin B₁.




Fig. 5: Scatchard plot of data for binding of aflatoxin B₁ to rabbit anti-aflatoxin B₁-histone H₁ antibodies. Scatchard equation for the law of mass action $b/c = kn - kb$ was made use of:

Where b is the molar ratio of bound aflatoxin B₁ to antibodies; c is the molar concentration of free aflatoxin B₁ at equilibrium; n is the average association constant for the binding at each site. Each point on the graph is the mean of the data obtained for the ten weeks under study. The intercept on the ordinate is K (the association constant for the first ligand bound) while the one on the abscissa is n (the average number of binding sites on each antibody molecule).

Determination of the protective effect of the antibodies on AFB₁-induced hepatic toxicities

The male wistar rats were divided into three groups (I, II, III) of twenty-five rats each. Rats in group I were immunized

intradermally with water in oil emulsion of AFB₁-H₁ complex (100 ug protein/kg body wt. of rat) while those in groups II and III had intradermal injection of saline. The animals were kept for four weeks after which the antibody titers of the immunized rats were determined. All the animals in groups I and II were then challenged with a single dose of pure AFB₁ in DMSO (7 mg/kg bd. wt.) by intraperitoneal injection and the mortality rate was monitored. The surviving rats were kept for two weeks after which they were bled via cardiac puncture and their livers aseptically excised.

1 g of the liver sample from each of the rats was separately homogenized in normal saline (3 volumes of liver wt.) and the protein content of the supernatant obtained on centrifugation (3,000 rpm for 15 mins) determined. Serum samples and supernatant from the liver homogenates (7.65 mg protein/ml) were analysed for alkaline phosphatase (ALP) and gamma glutamyl transferase (GT) activities. (Fig. 6). Limited histological examinations were also performed on the livers of the dead and surviving rats.

Results

AFB₁ was complexed to histone H₁ in the presence of S₉ microsomal activation mixture. The blue fluorescence in ultraviolet light characteristic of AFB₁ remained in the aqueous solution layer of AFB₁-H₁ complex from the first reaction medium after 10 minutes of vortexing with chloroform. The fluorescence was however extracted into the chloroform layer when the complex obtained from the second reaction medium in which the S₉ microsomal proteins were denatured before being added to the reaction mixture was similarly treated.

The electropherogram of AFB₁-H₁ complex (Fig.1) shows that the protein spots stained with Ponceau S correspond with the fluorescence spots of unstained duplicate electropherogram photographed under the long wavelength ultraviolet light.

The UV spectra in Figure 2 revealed that there was a red or bathochromic shift in the spectrum for AFB₁-H₁ and a blue or hypsochromic shift in the one for histone H₁ vis-à-vis the spectrum for AFB₁.

Antibodies were produced against AFB₁-H₁ complex in all the weeks studied with maximum production occurring in the ninth week after immunization. (Fig.3). The antibodies are specific for AFB₁ as demonstrated from the inhibition curve (Fig. 4). The average number of binding sites on the antibodies for AFB₁ is 1.94 with mean classical association constant of $34.5 \times 10^3 \text{ M}^{-1}$ and standard free energy change of -6.19 Kcal/mol. (Fig. 5).

The immunoprotective potential of the antibodies raised against AFB₁-H₁ complex was demonstrated by high mortality rate of the unimmunized rats and the reduced mean serum and liver ALP and GT activities in immunized rats compared to their unimmunized counterparts (Fig. 6) coupled with the reduction of AFB₁ induced hepatic lesions observed in the livers of rats immunized with AFB₁-H₁ complex before challenge with AFB₁.




Fig. 6: Effect of immunization with aflatoxin B₁-histone H₁ complex on serum and liver gamma glutamyl transferase and alkaline phosphatase in rats exposed to aflatoxin B₁

***** control, unimmunized and unchallenged rats.

////// Rats immunized with aflatoxin B₁-histone H₁ complex followed by challenge with aflatoxin B₁

!!!! Unimmunized rats challenged with aflatoxin B₁

Discussion

Earlier findings had shown that AFB₁ bind to histone H₁ (7) and that such binding may alters chromatin structure/function and gene expression *in vivo* (19). Our data presented on the *in vitro* coupling of AFB₁ to histone H₁ in the presence of S₉ activation mixture suggests that the bond between AFB₁ and histone H₁ in the synthesized complex is probably covalent. Such covalent bonds cannot be broken by solvent extraction of AFB₁-carrier molecules with chloroform. The electropherogram of AFB₁-H₁ in Figure 1 also support this observation. The UV spectra in Figure 2 clearly suggests that there has been a coupling of AFB₁ to histone H₁. Thus, this *in vitro* binding of AFB₁ to histone H₁ seem to have occur via the ultimate carcinogen AFB₁-2, 3-epoxide reacting directly with the epsilon amino group of the lysyl amino acid residues in the lysine rich histone H₁. Lysine had been shown to be the amino acid preferentially targeted by AFB₁ in proteins [20].

Animals immunized with carcinogen conjugated to proteins including AFB₁-protein conjugates have been shown to form antibodies that recognise the carcinogen [8, 21]. In this study, the specificity of antibodies to AFB₁-H₁ complex (Fig. 3) for AFB₁ was established from the fact that AFB₁ inhibited the binding of the antibodies to AFB₁-H₁ complex that induced their formation (Fig. 4). The mechanism of this inhibition seems to involve the formation of soluble complexes between the IgG antibodies and AFB₁ molecules thereby preventing the combination of the antibodies with the larger complete molecule of antigen which induce the formation of visible antigen-antibody complexes.

The average number of binding sites of 1.94 on the antibodies for AFB₁ and the mean classical association constant of $34.5 \times 10^3 \text{ M}^{-1}$ with standard free energy change of -6.19 Kcal/mol . (Fig. 5) suggest that the antibodies have high affinity for AFB₁. The polyclonal antibodies could therefore be useful *in vivo* and *in vitro* in immunodiagnosis and immunodetection of this mycotoxin in body fluids/tissues of populations at high or low risk of exposure to the toxin. Exposure of humans to aflatoxins had previously been assessed based on the detection of urinary metabolites of the toxin or by the presence of AFB₁ or its adducts in the peripheral blood and serum [10, 22]. It has been shown that AFB₁-DNA and AFB₁-H₁ adducts undergo rapid turnover after aflatoxin incorporation into the macromolecules before their excretion in urine [8]. Immunodetection of such adducts in urine using the studied antibodies may be more sensitive in giving informations on recent degree of exposure to AFB₁.

It is known that immunization with a carcinogen-protein conjugate may confer some protection against the effects of the specific carcinogen [23]. In this study, 45% of rats dosed with AFB₁ survived the toxic effects within three days of treatment while 70% of those immunized prior to challenge with AFB₁ survived the toxic effects within those days. The high mortality rate observed in the unimmunized rats may be attributed to the degree of acute toxicities of AFB₁. The protective effect of immunization reflected by the decreased mortality of the immunized rats may be due to the presence of AFB₁-specific antibodies produced against the AFB₁-H₁ complex. The antibodies may have intercepted the transport of the toxin to target sites and consequently inhibited its deleterious effects. The mean serum and liver ALP and

GT activities of unimmunized rats dosed with AFB₁ which are higher than those observed for the immunized rats dosed with AFB₁ and the control rats which were not immunized nor dosed with AFB₁ (Fig. 6) shows that AFB₁ toxic effects induced increased synthesis of ALP and GT in the damaged liver as well as leakage of the enzyme into the serum. Limited histological examination on the rat liver following exposure to AFB₁ revealed that the liver from unimmunized rats dosed with AFB₁ show severe bile duct hyperplasia, necrotic and vacuolated hepatocytes and enlarged hyperchromatic hepatocyte nuclei. Marked reduction of these lesions was observed in the liver of rats immunized before challenge with the toxin. This further suggests that immunization of the rats with the complex prior to challenge with AFB₁ do protect them against chronic and acute toxic effects that resulted from exposure to the mycotoxin. Therefore, it may be possible to use AFB₁-H₁ complex and other AFB₁-protein conjugates in animals and may be humans for immunoprophylaxis. Further studies are being directed at verifying whether immunization with the complex will actually inhibit AFB₁ induced hepatocarcinogenic effects and thus its probable use in vaccine development.

References

1. Uwaifo AO; Billings PC and Heidelberger C: Mutation of Chinese hamster V79 cells and transformation and mutagenicity of mouse

- fibroblast C3H/10T1/2 clone 8 cells by aflatoxin B₁ and four other furocoumarins isolated from two Nigerian medicinal plants. *Cancer Res.* 1983; 43: 1054-1058.
2. Potchinsky MB and Bloom SE: Selective aflatoxin B₁ induced sister chromatid exchanges and cytotoxicity in differentiating B and T lymphocytes *in vivo*. *Environ. Mol. Mutagen.*, 1993; 21(1): 87-94.
3. Verma RJ; Kolhe AS and Chaudhri SB: Intracellular calcium accumulation during flatoxicosis. *Med. Sci. Res.*, 1998; 26 (5): 339-341.
4. Dirr HW and Schbort JC: Aflatoxin B₁ transports in rat blood plasma. Binding to albumin *in vivo* and *in vitro* and spectrofluometric studies into the nature of the interaction. *Biochem. Biophys. Acta.*, 1986; 811: 383-390.
5. Irvin TR and Wogan GN: Quantitative and qualitative characterisation of aflatoxin B₁ adducts formed *in vivo* with the ribosomal RNA genes of rats liver DNA. *Cancer. Res.* 1985; 45: 3497-3502.
6. Lyman BA; Erki L; Bledrzycka DW *et al.*: Modification of protein synthetic components by aflatoxin B₁. *Biochem. Pharmacol.* 1988; 37 1481-1486.
7. Groopman JD; Busby WF Wogan GN: Nuclear distribution of aflatoxin B₁ and its interaction with histones in rat liver *in vivo*. *Cancer. Res.*, 1980; 40: 4343-4351.
8. Ryder GC and Montesano R: Monitoring of aflatoxin in human body fluids and applications to field studies. *Cancer. Res.*, 1985; 45: 922-937.
9. Kaveri SV; Fremy JM; Lapeyee C and Strosbera AD: Immunodetection and immunopurification of aflatoxins using a high affinity monoclonal antibody to aflatoxin B₁. *Lett. Appl. Microbiol.* 1987; 4: 71-75.
10. Wild CP; Hudson GJ; Sabbioni G *et al.*: Dietary intake of aflatoxins and the level of albumin bound aflatoxin in peripheral blood in The Gambia, West Africa. *Cancer. Epidemiol. Biomarkers. Prev.* 1992; 1(3): 229-234.
11. Maron DM and Ames BN: Revised methods for the Salmonella mutagenicity test. *Mutat. Res.* 1983; 113; 173-215.
12. Gurtoo HL: On the binding of aflatoxin B₁ and its metabolites to hepatic microsomes. *Biochem. Biophys. Res. Commun.* 1973; 50: 649-655.
13. Essigmann JM; Croy RC; Nadzan *et al.*: Structural identification of the major DNA adducts formed by aflatoxin B₁ *in vitro*. *Proc. Natl. Acad. Sci. (USA)* 1977; 74: 1870-1874.
14. Chu FS: Studies on ochratoxins. *Crit. Rev. Toxicol.* 1974; 2: 499-524.
15. Chu FS and Ueno I: Production of antibodies against aflatoxin B₁. *Appl. Environ. Microbiol.* 1977; 33: 1125-1128.
16. Karush F; Karush SS; Eisen HN and McGuign JE:

- Hapten reaction and kinetics of interaction with antibodies. B. Equilibrium dialysis and C. Quenching of antibody fluorescence by hapten and antigens. In: Williams C and Chase MW eds. *Methods in immunology and immunochemistry*. Academic Press, New York 1971; 383-406.
17. O'Reilly RA: Studies on the coumarin anticoagulant drugs: Interaction of human plasma albumin and warfarin sodium. *J. Clin. Invest.* 1967; 46: 829.
 18. Scatchard G: The attractions of proteins for small molecules and ions. *Am. N.Y. Acad. Sci.*, 1949; 51: 660-672.
 19. Gurley LR; D'Aanna JA; Barham SS *et al.* Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. *Eur. J. Biochem.* 1978; 84: 1-15.
 20. Sabbioni G: Chemical and physical properties of the major serum albumin adduct of aflatoxin B₁ and their implications for the quantification in biological samples. *Chem. Biol. Inter.*, 1990; 75: 1-15.
 21. Butter VP and Beiser SM: Antibodies to small molecules; biological and clinical applications. *Advance Immuno.* 1973; 17: 255-309.
 22. Groopmn JD; Gain LG and Kenslew TW: Aflatoxin exposure in human populations: - Measurements and relationships to cancer. *CRC Crit. Rev. Toxicol.* 1988; 19: 113-145.
 23. Franks WR and Creech HJ: Chemoantigens and carcinogenesis. *Am. J. Cancer.* 1939; 29: 260-268.